Positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of talazoparib, an oral poly ADP-ribose polymerase (PARP) inhibitor in combination with enzalutamide, an androgen receptor pathway inhibitor, for metastatic castration-resistant prostate cancer (mCRPC) are to be shared with global health authorities to potentially update the talazoparib approved label. ...
CRPC
Advertisement
Latest News
Dr. Dorff shares highlights from Uromigos Live 2024 and talks about the role of ADT in prostate cancer treatment.
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
Dr. Oliver Sartor gives an overview of the SPLASH trial on PSMA-targeted therapies for patients with prostate cancer.
Experts at ESMO Congress 2024 discuss novel therapies for castration-resistant prostate cancer.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
The first part of five segments from the live podcast, roundtable session on radioligands.
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
Advertisement
Advertisement
Latest News
The first part of five segments from the live podcast, roundtable session on radioligands.
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.